Manchester Keith S insider trades
Manchester Keith S has filed 18 Form 4s with the SEC that we hold, for Roivant Sciences Ltd. (ROIV) (Director) and Arbutus Biopharma Corp (ABUS) (Director). Across all of them we count 0 purchases worth $0 and 31 sales worth $258.7M reported on Form 4. In the last 12 months: 0 purchases ($0) and 20 sales ($154.5M). The largest single trade was a sale of 3,059,368 shares of Roivant Sciences Ltd. worth $35.3M, dated 2023-09-28. The first filing on our record is dated 2022-05-26 and the latest 2026-09-18.
Roivant Sciences Ltd. (ROIV)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2022-11-10 | S, sale reported on Form 4 | 146,079 | $693.9K | 2022-11-14 |
| 2022-11-10 | S, sale reported on Form 4 | 2,311,643 | $11.0M | 2022-11-14 |
| 2022-11-10 | S, sale reported on Form 4 | 372,427 | $1.8M | 2022-11-14 |
| 2022-11-10 | S, sale reported on Form 4 | 1,092,355 | $5.2M | 2022-11-14 |
| 2023-09-28 | S, sale reported on Form 4 | 446,394 | $5.2M | 2023-10-02 |
| 2023-09-28 | S, sale reported on Form 4 | 1,104,599 | $12.8M | 2023-10-02 |
| 2023-09-28 | S, sale reported on Form 4 | 2,285,783 | $26.4M | 2023-10-02 |
| 2023-09-28 | S, sale reported on Form 4 | 3,059,368 | $35.3M | 2023-10-02 |
| 2024-09-24 | S, sale reported on Form 4 | 368,052 | $4.3M | 2024-09-26 |
| 2024-09-25 | S, sale reported on Form 4 | 134,948 | $1.6M | 2024-09-26 |
| 2025-11-19 | S, sale reported on Form 4 | 850,000 | $17.2M | 2025-11-21 |
| 2025-11-19 | S, sale reported on Form 4 | 150,000 | $3.0M | 2025-11-21 |
| 2025-11-19 | S, sale reported on Form 4 | 125,000 | $2.5M | 2025-11-21 |
| 2025-11-19 | S, sale reported on Form 4 | 175,000 | $3.5M | 2025-11-21 |
| 2025-12-16 | S, sale reported on Form 4 | 275,000 | $6.3M | 2025-12-18 |
| 2025-12-16 | S, sale reported on Form 4 | 642,282 | $14.8M | 2025-12-18 |
| 2025-12-17 | S, sale reported on Form 4 | 189,538 | $4.4M | 2025-12-18 |
| 2025-12-17 | S, sale reported on Form 4 | 432,718 | $10.0M | 2025-12-18 |
| 2025-12-17 | S, sale reported on Form 4 | 155,076 | $3.6M | 2025-12-18 |
| 2026-02-11 | S, sale reported on Form 4 | 425,000 | $11.3M | 2026-02-13 |
| 2026-02-12 | S, sale reported on Form 4 | 275,000 | $7.4M | 2026-02-13 |
| 2026-02-12 | S, sale reported on Form 4 | 150,000 | $4.0M | 2026-02-13 |
| 2026-02-13 | S, sale reported on Form 4 | 150,784 | $4.0M | 2026-02-13 |
| 2026-02-13 | S, sale reported on Form 4 | 225,000 | $6.0M | 2026-02-13 |
| 2026-06-26 | S, sale reported on Form 4 | 325,000 | $11.1M | 2026-06-30 |
| 2026-06-26 | S, sale reported on Form 4 | 300,783 | $10.2M | 2026-06-30 |
| 2026-06-29 | S, sale reported on Form 4 | 600,000 | $20.8M | 2026-06-30 |
| 2026-06-29 | S, sale reported on Form 4 | 200,000 | $6.9M | 2026-06-30 |
| 2026-06-30 | S, sale reported on Form 4 | 200,000 | $7.1M | 2026-06-30 |
| 2026-06-30 | S, sale reported on Form 4 | 12,380 | $436.8K | 2026-06-30 |
Arbutus Biopharma Corp (ABUS)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2024-08-14 | S, sale reported on Form 4 | 8,846 | $32.6K | 2024-08-16 |
Counted from the Form 4 filings this reporting owner (SEC CIK 1244828) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms